Neupro

Indicated For

Parkinson's disease, Restless Legs Syndrome

About This Medication

# UCB Patient Assistance Program Patient Guide: How to Get Neupro (rotigotine) at Low or No Cost Neupro (rotigotine) is a prescription transdermal patch used to treat symptoms of Parkinson's disease and moderate-to-severe restless legs syndrome (RLS). The **UCB Patient Assistance Program** offers eligible patients free medication if you meet specific residency, insurance, and financial criteria[1][2][3]. ## About Neupro (rotigotine) **Neupro** is a once-daily patch applied to clean, dry, intact skin on areas like the abdomen, thigh, hip, flank, shoulder, or upper arm. It delivers rotigotine continuously over 24 hours to help manage motor symptoms in early-stage Parkinson's disease or advanced stages with or without levodopa, and symptoms of moderate-to-severe primary RLS[5][8]. Common side effects include skin reactions at the application site, nausea, sleepiness, dizziness, and application site reactions. Always follow your doctor's instructions for use, rotation of sites, and storage. Report side effects to your doctor or UCB at 1-844-599-2273[1][5]. This guide explains how to access **Neupro** through the UCB Patient Assistance Program (PAP), designed for patients facing financial hardship. The program ships medication directly to you at no cost if approved[1][2][6]. ## Who Qualifies for the Program? To qualify, you must meet **all minimum eligibility requirements**: - Reside in the United States, District of Columbia, Puerto Rico, or U.S. Territory[1][2][6]. - Be **uninsured** (no prescription coverage) or **insured medically but with no prescription drug coverage** (underinsured). Patients with **certain Medicare Part D plans** may qualify—apply to confirm[1][2][6]. - Demonstrate **financial need** through income verification. Financial criteria apply, typically up to **300% of the Federal Poverty Level (FPL)** based on household size, though exact thresholds require contacting the program as they may change[6]. Proof of income is **mandatory**[1][2]. - Have a valid prescription for Neupro from a U.S.-licensed healthcare provider[1][6]. **Important notes**: - Program not for institutions like clinics or hospitals[1][2]. - Additional product-specific criteria may apply; eligibility subject to change without notice[2]. - If you don't meet minimums, call 1-844-599-CARE (2273) for other UCB resources[1][2][5]. ## Income Eligibility Breakdown Financial eligibility requires **proof of income** for all household members. If no income, submit a signed letter explaining this[2]. Exact thresholds aren't publicly fixed but generally align with **up to 300% FPL** for household income[6]. Contact the program for current details, as criteria evolve[1][2]. Here's a sample table based on 2026 Federal Poverty Guidelines (approximate; verify with program): | Household Size | 100% FPL | 200% FPL | 300% FPL (Typical Max) | |----------------|----------|----------|------------------------| | 1 (Individual) | $15,060 | $30,120 | **$45,180**[6] | | 2 (Couple) | $20,440 | $40,880 | **$61,320** | | 3 | $25,820 | $51,640 | **$77,460** | | 4 | $31,200 | $62,400 | **$93,600** | *Add ~$5,380 per additional person for FPL. These are estimates—**call (844) 599-2273** for precise 2026 thresholds and verification methods (e.g., W-2, pay stubs, tax returns)[1][2][6].* ## Insurance Requirements - **Uninsured**: No prescription coverage required[1][6]. - **Underinsured**: Medically insured OK, but **no prescription drug coverage**. Medicare Part D patients with **certain plans** or **significant financial hardship** may qualify—apply to check[1][2][6]. - **Exclusions**: Generally not for those with full prescription coverage, Medicaid (in some older docs), or high income[1][7]. UCB verifies insurance status[2]. ## Step-by-Step Application Process Applications are **mailed**—no online URL provided, but check ucb-usa.com for updates[3]. 1. **Download or Request Form**: Get the UCB PAP application from ucb-usa.com/Patients/Financial-Assistance or call (844) 599-2273[1][2][3]. 2. **Complete Patient Sections (1 & 2)**: Provide personal info, household size, income details (all required), and sign. **Proof of income MUST be included** (e.g., W-2, pay stubs)[1][2]. 3. **Physician Completes Section 3**: Doctor fills prescriber section and attaches a **written prescription** for Neupro[1][2]. 4. **Gather Documents**: - Proof of income - Prescription - Physician-completed application section[program details]. 5. **Mail Application**: Send to address on form (e.g., UCB, Inc., Smyrna, GA—confirm via phone)[1][7]. 6. **Wait for Review**: Processing takes 4-6 weeks typically[7]. **Tip**: Print clearly; incomplete apps delay or deny[1]. For help, call UCBCares at (844) 599-2273[1][2][5]. ## Timeline and Delivery - **Processing**: Allow **4-6 weeks** for review and shipping[7]. Newer info suggests variable times—call for updates[1][2]. - **Approval Duration**: Up to **12 months**; reapply annually[6]. - **Delivery**: **Shipped free directly to patient** (not doctor)[program details][6]. - Track status by calling (844) 599-2273[1]. ## Alternatives if Denied - **Contact UCBCares**: Call (844) 599-2273 for other financial resources, co-pay help, or referrals[1][2][5][9]. - **Third-Party Help**: Services like Simplefill (877-386-0206) assist with apps[6]. - **Other Programs**: Check NeedyMeds, RxAssist, or PAN Foundation for Parkinson's/RLS aid. - **Generic/Biosimilars**: None listed for Neupro[program details]. - **Medicare Extra Help**: If on Part D, apply for Low-Income Subsidy. - **State Programs**: Local Medicaid or charity clinics. ## Disclaimer This guide is for informational purposes based on available program details as of 2026. **Eligibility, rules, and benefits can change without notice**—always verify with UCB at (844) 599-2273[1][2]. Not medical advice; consult your doctor. UCB may verify all info and denies fraudulent apps. Program not guaranteed; other coverage may affect eligibility[2]. Report side effects to FDA at 1-800-FDA-1088[5]. (Word count: 1028)

Program information last verified: March 30, 2026